| Description | Sudubrilimab (HS636), an Ig G1-kappa monoclonal antibody targeting PDL1, is engineered with a TGF-β1 receptor II ectodomain (TGFBR2-ECD) fused to its C-terminus. This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 pathway and TGF-β bioactivity within the immunosuppressive tumor microenvironment [1]. |
| molecular weight | N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |